Bauducel M, Piriou V, Dussart C, Aulagner G, Armoiry X
Service d'anesthésie-réanimation, hospices civils de Lyon, groupement hospitalier Sud, Claude-Bernard université Lyon 1, 69310 Pierre-Bénite, France.
Service d'anesthésie-réanimation, hospices civils de Lyon, groupement hospitalier Sud, Claude-Bernard université Lyon 1, 69310 Pierre-Bénite, France.
Ann Pharm Fr. 2017 Jul;75(4):276-284. doi: 10.1016/j.pharma.2017.02.001. Epub 2017 Mar 24.
Phenylephrine, ephedrine and norepinephrine are the vasopressors most commonly used in the operating room to treat anaesthesia-induced hypotension. Two new diluted forms of phenylephrine were released in 2011 (500μg/10mL and 500μg/5mL). We initiated a study to evaluate trends in the use of vasopressors in the operating room in French hospitals over the period 2011-2014.
We conducted a longitudinal, retrospective, observational study between 2011 and 2014 in French teaching and military hospitals. A questionnaire was sent in February 2015 to hospital pharmacists of each centre to retrospectively collect the consumption of each type of vasopressor. Yearly numbers of vasopressor ampoules were divided by the yearly numbers of anaesthetics recorded. For each vasopressor, we calculated the number of ampoules per 100 anaesthetics recorded (/100A).
Thirty-two hospitals (82%) completed the questionnaire. One hundred per cent of hospitals had registered the diluted form of phenylephrine (61% had chosen the dilution 500μg/10mL), whereas concentrated ampoules were available in 68% of hospitals. Over the period, an exponential increase in the use of diluted phenylephrine was observed (from 1.0 ampoule/100A in 2012 to 31.7 in 2014), the use of ephedrine remained stable (26 ampoules and 17 prefilled syringe/100A), and use of norepinephrine trended upwards (from 6.7 to 8.2 ampoules/100A).
The use of diluted phenylephrine has exponentially increased without reducing consumption of other vasopressors. This trend might be secondary to practice changes in hypotension treatment following the release of French guidelines in 2013 related to fluid management, the restriction of indications of hydroxylethyl-starch solutions in 2013, and a better knowledge of the benefit of blood pressure optimisation to reduce postoperative morbidity.
去氧肾上腺素、麻黄碱和去甲肾上腺素是手术室中最常用于治疗麻醉引起的低血压的血管升压药。2011年推出了两种新的稀释形式的去氧肾上腺素(500μg/10mL和500μg/5mL)。我们开展了一项研究,以评估2011 - 2014年期间法国医院手术室中血管升压药的使用趋势。
我们在2011年至2014年期间对法国教学医院和军队医院进行了一项纵向、回顾性观察研究。2015年2月向每个中心的医院药剂师发送了一份问卷,以回顾性收集每种血管升压药的消耗量。每年血管升压药安瓿瓶数量除以每年记录的麻醉剂数量。对于每种血管升压药,我们计算每100例记录的麻醉剂的安瓿瓶数量(/100A)。
32家医院(82%)完成了问卷。100%的医院记录了稀释形式的去氧肾上腺素(61%选择了500μg/10mL的稀释液),而68%的医院有浓缩安瓿瓶。在此期间,观察到稀释去氧肾上腺素的使用呈指数增长(从2012年的1.0安瓿瓶/100A增至2014年的31.7),麻黄碱的使用保持稳定(26安瓿瓶和17支预充注射器/100A),去甲肾上腺素的使用呈上升趋势(从6.7增至8.2安瓿瓶/100A)。
稀释去氧肾上腺素的使用呈指数增长,而未减少其他血管升压药的消耗量。这种趋势可能是由于2013年法国发布的与液体管理相关的指南、2013年对羟乙基淀粉溶液适应症的限制以及对优化血压以降低术后发病率益处的更好了解后,低血压治疗实践发生了变化。